1. Discovery of Novel, Potent Inhibitors of Hydroxy Acid Oxidase 1 (HAO1) Using DNA-Encoded Chemical Library Screening
- Author
-
Shilpi Arora, Anna Kohlmann, Christopher D. Hupp, Julie Liu, Christelle Huguet, Allison Olszewski, Moritz von Rechenberg, John W. Cuozzo, Ying Zhang, Katy E Georgiadis, Matthew A. Clark, Esther C.Y. Lee, Charles J. Eyermann, Andrew J. McRiner, Paolo A. Centrella, Michael I Monteiro, Anthony D. Keefe, Benjamin Levin, Andrew D. Ferguson, Zooey Wang, and Yanbin Liu
- Subjects
Male ,Indoles ,Crystallography, X-Ray ,01 natural sciences ,Chemical library ,Small Molecule Libraries ,Mice ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,Pharmacokinetics ,Drug Discovery ,Animals ,Humans ,Structure–activity relationship ,Potency ,Transaminases ,030304 developmental biology ,ADME ,0303 health sciences ,Oxidase test ,Binding Sites ,Chemistry ,DNA ,Metabolism ,0104 chemical sciences ,Molecular Docking Simulation ,Alcohol Oxidoreductases ,Thiazoles ,010404 medicinal & biomolecular chemistry ,Biochemistry ,Drug Design ,Hyperoxaluria, Primary ,Molecular Medicine ,Glucuronide ,Half-Life - Abstract
Inhibition of hydroxy acid oxidase 1 (HAO1) is a strategy to mitigate the accumulation of toxic oxalate that results from reduced activity of alanine-glyoxylate aminotransferase (AGXT) in primary hyperoxaluria 1 (PH1) patients. DNA-Encoded Chemical Library (DECL) screening provided two novel chemical series of potent HAO1 inhibitors, represented by compounds 3-6. Compound 5 was further optimized via various structure-activity relationship (SAR) exploration methods to 29, a compound with improved potency and absorption, distribution, metabolism, and excretion (ADME)/pharmacokinetic (PK) properties. Since carboxylic acid-containing compounds are often poorly permeable and have potential active glucuronide metabolites, we undertook a brief, initial exploration of acid replacements with the aim of identifying non-acid-containing HAO1 inhibitors. Structure-based drug design initiated with Compound 5 led to the identification of a nonacid inhibitor of HAO1, 31, which has weaker potency and increased permeability.
- Published
- 2021